Last reviewed · How we verify
NCT04137705: MORIS
MultiOrgan Multi-Parametric MRI Study
trial testing Multiparametric MRI in Type 2 Diabetes in 43 participants. Completed in 25 November 2023.
25 November 2023
Quick facts
| Lead sponsor | Perspectum |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 4 November 2019 |
| Primary completion | 25 November 2023 |
| Estimated completion | 25 November 2023 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- Multiparametric MRI
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Perspectum
Who can join
18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the reproducibility of a single quantitative multiparametric MRI for the assessment of body composition and multiple organ structures.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Repeatability, Reproducibility, and Observer Variability of Cortical T1 Mapping for Renal Tissue Characterization.
Nowak M, Henningsson M, Davis T, Chowdhury N, et al · · 2025 · cited 4× · PMID 39468402 · DOI 10.1002/jmri.29602
Verify or expand the search:
- PubMed search for NCT04137705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Multiparametric MRI
Trials testing the same drug.
- NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
- NCT03180398 — Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients · NA · terminated
- NCT03979573 — Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer · NA · unknown
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Perspectum trials
Trials by the same sponsor.
- NCT07098650 — Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System · recruiting
- NCT04974710 — Developing an US-MRI Biomarker Fusion Model for Endometriosis · completed
- NCT05326191 — First-trimester Placental Ultrasound Study · completed
- NCT05000242 — West Hertfordshire Inflammatory Bowel Disease Technology Study · active not recruiting
- NCT05110248 — Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04137705 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Perspectum
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04137705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing